Following the successful treatment of Whitehead, Grupp and his research team published their findings on two pediatric patients who had a complete remission of cancer following this treatment. As a result of his medical achievements, Grupp was chosen by John M. Maris, director of the Center for Childhood Cancer Research at CHOP, to serve on the research team for his project "Immunogenomics to Create New Therapies for High-Risk Childhood Cancers." He continued to work on personalized cellular therapy and in 2014, published findings that showed 90% of children and adults with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy (CTL019). In recognition of his work, Grupp was the co-recipient of the Pennsylvania Bio’s Patient Impact Award and Frank A. Oski Lectureship from the American Society of Pediatric Hematology/Oncology.
